Candel Therapeutics Announces Presentations Of Key Clinical Data At AdMeTech And European Association Of Neuro-Oncology Conferences In September 2021
Candel Therapeutics, Inc. (NASDAQ:CADL), today announced upcoming presentations of clinical data supporting continued clinical advancement of its prostate cancer and brain cancer programs at the following medical
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
54 Biggest Movers From Yesterday
Gainers
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) shares jumped 111.8% to settle at $27.17 on Wednesday after jumping 50% on Tuesday.
Mid-Afternoon Market Update: Kadmon Surges Following Acquisition News; UiPath Shares Drop
Toward the end of trading Wednesday, the Dow traded down 0.24% to 35,015.62 while the NASDAQ fell 0.61% to 15,280.10. The S&P also fell, dropping 0.20% to 4,510.78.
Mid-Day Market Update: Crude Oil Rises 1%; REV Group Shares Plummet
Midway through trading Wednesday, the Dow traded down 0.45% to 34,942.88 while the NASDAQ fell 1.09% to 15,207.45. The S&P also fell, dropping 0.55% to 4,495.35.
30 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Kadmon Holdings, Inc. (NASDAQ: KDMN) shares jumped 72.6% to $9.15. Sanofi announced Wednesday it has agreed to acquire New York-based biopharma Kadmon in a $1.9 billion all-cash deal.
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)
72 Biggest Movers From Yesterday
Gainers
Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.
Candel Therapeutics Completes Enrollment In Phase 3 Clinical Trial Of CAN-2409 In Combination With Valacyclovir For The Treatment Of Intermediate-High Risk Localized Prostate Cancer
Candel Therapeutics, Inc. (“Candel”) (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has completed patient enrollment